Teva gets FDA green light for first generic SabrilTeva has received the Food and Drug Administration's approval for the first generic of Lundbeck's Sabril. Teva, Amgen resolve generic Sensipar disputeTeva has agreed to stop selling its generic Sensipar after settling recent litigation with Amgen. AAM joins newly formed Coalition Against Patent Abuse The Association for Accessible Medicines has joined the Coalition Against Patent Abuse, a new stakeholder association that is focused on fighting abuses of the patent system. Ferring Pharmaceuticals acquires generic ganirelix acetate injection rights Ferring has acquired U.S. commercialization rights for generic ganirelix acetate injection from Sun Pharma. Amneal gets FDA nod for generic Exelon patch The FDA has approved Amneal's generic Exelon patch, which had a market value of roughly $225 million. Camber launches generic Albenza Camber is debuting a generic Albenza for the treatment of tapeworms and other parasites. FDA approves Lupin's generic Latuda Lupin has received the FDA's approval for generic Latuda tablets, which had a market value of roughly $3.2 billion. Alembic gets approval for 2 generics The FDA has approved Alembic's generic Mirapex and Patanol, which had a market value of roughly $38.6 million, and $61 million, respectively. Lupin's generic Onfi gets FDA approval Lupin has received the Food and Drug Administration's green light for generic Onfi, which had a market value of roughly $260.2 million. Slayback gets FDA nod for generic Makena The Food and Drug Administration has approved Slayback Pharma's generic Makena, which is available in a multidose vial. First Previous 202 203 204 205 206 Next Last
